Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | KD033, a PDL1-1L15 bispecific molecule for the treatment of cancer

Jason Luke, MD, FACP, UPMC Hillman Cancer Center, Pittsburgh, PA, describes the mechanism of action of the PDL1-IL15 bispecific molecule, KD033. Early dose-escalation clinical trial data of PDL1-IL15 have demonstrated responses in the form of fevers and chills and even disease regression in some patients. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.